H. Meltzer

发表

Ziprasidone in the long-term treatment of negative symptoms and prevention of exacerbation of schizophrenia

M. Aratô, R. O'Connor, J. Bradbury, 1998, European Psychiatry.

Clozapine in treatment-resistant schizophrenics.

J. Kane, G. Honigfeld, J. Singer, 1988, Psychopharmacology bulletin.

The efficacy and tolerability of sertindole in schizophrenic patients: A pilot, double-blind, placebo-controlled, dose-ringing study

D. Kammen, V. Shu, J. McEvoy, 1993, Schizophrenia Research.

Ziprasidone and the Corrected QT Interval

T. Tensfeldt, A. Camm, J. Kane, 2012, CNS Drugs.

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

G Honigfeld, H. Meltzer, J. Kane, 1988, Archives of general psychiatry.

Serotonergic Dysfunction in Depression

H. Meltzer, 1989, British Journal of Psychiatry.

Development and Validation of a Computerized Adaptive Assessment Tool for Discrimination and Measurement of Psychotic Symptoms.

R. Gibbons, J. Kane, Bhagyashree Patil, 2020, Schizophrenia bulletin.

Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia

D. Hilt, R. Keefe, I. Lombardo, 2015, Neuropsychopharmacology.

Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial

Chuanchieh Hsu, Steven G Potkin, Ravi Anand, 2003, Biological Psychiatry.

Clozapine for the treatment-resistant schizophrenic: results of a US multicenter trial

J. Kane, G. Honigfeld, The 600A-GAP-BE Study Group, 1989, Psychopharmacology.